Literature DB >> 15936542

Long-term parotid gland function after radiotherapy.

Pètra M Braam1, Judith M Roesink, Marinus A Moerland, Cornelis P J Raaijmakers, Maria Schipper, Chris H J Terhaard.   

Abstract

PURPOSE: Irradiation of the parotid glands causes salivary dysfunction, resulting in reduced salivary flow. Recovery can be seen with time; however, long-term prospective data are lacking. The objective of this study was to analyze the long-term parotid gland function after irradiation for head-and-neck cancer. METHODS AND MATERIALS: A total of 52 patients with head-and-neck cancer and treated with radiotherapy (RT) were prospectively evaluated. Stimulated bilateral parotid salivary flow rates were measured before RT and 6 weeks, 6 months, 12 months, and at least 3.5 years after RT completion. A complication was defined as a stimulated parotid flow rate of <25% of the pre-RT flow rate. The normal tissue complication probability model proposed by Lyman was fit to the data. Multilevel techniques were used to model the patterns of flow rates with time.
RESULTS: The mean stimulated flow rate of the parotid glands before RT was 0.31 mL/min (standard deviation [SD], 0.21). This was reduced to 0.14 mL/min (SD, 0.15) at 6 weeks after RT and recovered to 0.20 mL/min (SD, 0.22) at 6 months and 0.19 mL/min (SD, 0.21) at 12 months after RT. The mean stimulated flow rate was 0.25 mL/min (SD, 0.28) 5 years after RT. The mean dose to the parotid gland resulting in a 50% complication probability increased from 34 Gy at 6 weeks to 40 Gy at 6 months, 42 Gy at 12 months, and 46 Gy at 5 years after RT. Multilevel modeling indicated that both dose and time were significantly associated with the flow ratio.
CONCLUSION: Salivary output can still recover many years after RT. At 5 years after RT, we found an increase in the salivary flow rate of approximately 32% compared with at 12 months after RT.

Entities:  

Mesh:

Year:  2005        PMID: 15936542     DOI: 10.1016/j.ijrobp.2004.12.015

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  27 in total

1.  Parotid gland-recovery after radiotherapy in the head and neck region--36 months follow-up of a prospective clinical study.

Authors:  Jeremias Hey; Juergen Setz; Reinhard Gerlach; Martin Janich; Guido Hildebrandt; Dirk Vordermark; Christian R Gernhardt; Thomas Kuhnt
Journal:  Radiat Oncol       Date:  2011-09-27       Impact factor: 3.481

Review 2.  Surgery Versus Radiotherapy for Early Oropharyngeal Tumors: a Never-Ending Debate.

Authors:  Yan Monnier; Christian Simon
Journal:  Curr Treat Options Oncol       Date:  2015-09

3.  Texture analysis as a predictor of radiation-induced xerostomia in head and neck patients undergoing IMRT.

Authors:  Valerio Nardone; Paolo Tini; Christophe Nioche; Maria Antonietta Mazzei; Tommaso Carfagno; Giuseppe Battaglia; Pierpaolo Pastina; Roberta Grassi; Lucio Sebaste; Luigi Pirtoli
Journal:  Radiol Med       Date:  2018-01-24       Impact factor: 3.469

4.  The dental management of a mouth cancer patient.

Authors:  N G Beacher; M P Sweeney
Journal:  Br Dent J       Date:  2018-11-09       Impact factor: 1.626

5.  Impact of non-compliance with oral care on radiation caries in head and neck cancer survivors.

Authors:  Sudhir Bhandari; Bhavita Wadhwa Soni; Sushmita Ghoshal
Journal:  Support Care Cancer       Date:  2021-02-01       Impact factor: 3.603

6.  Sparing the region of the salivary gland containing stem cells preserves saliva production after radiotherapy for head and neck cancer.

Authors:  Peter van Luijk; Sarah Pringle; Joseph O Deasy; Vitali V Moiseenko; Hette Faber; Allan Hovan; Mirjam Baanstra; Hans P van der Laan; Roel G J Kierkels; Arjen van der Schaaf; Max J Witjes; Jacobus M Schippers; Sytze Brandenburg; Johannes A Langendijk; Jonn Wu; Robert P Coppes
Journal:  Sci Transl Med       Date:  2015-09-16       Impact factor: 17.956

7.  Assessment of xerostomia and its impact on quality of life in head and neck cancer patients undergoing radiation therapy.

Authors:  Pinelopi-Theopisti Memtsa; Maria Tolia; Ioannis Tzitzikas; John Bizakis; Kyriaki Pistevou-Gombaki; Martha Charalambidou; Chrysoula Iliopoulou; George Kyrgias
Journal:  Mol Clin Oncol       Date:  2017-03-17

8.  Xerostomia Quality of Life Scale (XeQoLS) questionnaire: validation of Italian version in head and neck cancer patients.

Authors:  Luciana Lastrucci; Silvia Bertocci; Vittorio Bini; Simona Borghesi; Roberta De Majo; Andrea Rampini; Pietro Giovanni Gennari; Paola Pernici
Journal:  Radiol Med       Date:  2017-08-31       Impact factor: 3.469

9.  Recombinant AAV9-TLK1B administration ameliorates fractionated radiation-induced xerostomia.

Authors:  Prakash Srinivasan Timiri Shanmugam; Robert D Dayton; Senthilnathan Palaniyandi; Fleurette Abreo; Gloria Caldito; Ronald L Klein; Gulshan Sunavala-Dossabhoy
Journal:  Hum Gene Ther       Date:  2013-06       Impact factor: 5.695

10.  Predictive Models to Determine Clinically Relevant Deviations in Delivered Dose for Head and Neck Cancer.

Authors:  Molly M McCulloch; Choonik Lee; Benjamin S Rosen; Justin D Kamp; Chrissy M Lockhart; Jae Y Lee; Daniel F Polan; Peter G Hawkins; Carlos J R Anderson; Jolien Heukelom; Jan-Jakob Sonke; Clifton D Fuller; James M Balter; Randall K Ten Haken; Avraham Eisbruch; Kristy K Brock
Journal:  Pract Radiat Oncol       Date:  2019-03-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.